GlycanAge key facts
as of Oct 2026- Developer of a biological age test designed to discover, measure, and optimize longevity.
- GlycanAge is valued at approximately $17.0M as of Oct 2026 (last reported valuation).
- It has raised $15.5M; the latest was Later Stage VC ($8.7M) in Aug 2025.
- Notable investors include Pareto Holdings, European Union, Hub71, Exceptional Ventures, Vesna Deep Tech Fund — 24 tracked in total.
- Status: Privately Held (backing).
GlycanAge's last reported valuation, Jan 2024. Nothing priced has surfaced since.
- ·The complete investor list: 24 names
- ·Watch GlycanAge: the Monday email on marks, rounds and moves
GlycanAge funding rounds
No funding rounds for GlycanAge are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs GlycanAge
24+GlycanAge valuation
GlycanAge's last reported valuation was $17 million in Jan 2024. No priced round, secondary trade or fund mark has surfaced since.
GlycanAge investors
24 investors are on record for GlycanAge, including Pareto Holdings, European Union, Hub71 and Exceptional Ventures.
About GlycanAge
Developer of a biological age test designed to discover, measure, and optimize longevity. The company collects a few drops of blood with a quick finger-prick test with analysis, viewing results in a personal online dashboard, and consulting with care throughout the process, enabling patients to know food intolerances and their true age.
- Sector
- Healthcare
- HQ
- Newcastle Upon Tyne, United Kingdom
- Founded
- 2016
- Employees
- 42
- Website
- glycanage.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.